Loading…

Endoscopic management of duodenal adenomas in patients with familial adenomatous polyposis

Almost all patients with familial adenomatous polyposis (FAP) develop duodenal adenomas, with a 4% to 18% risk of progression into duodenal cancer. Prophylactic endoscopic resection of duodenal adenomas may prevent cancer and is considered safer than surgical alternatives; however, data are limited....

Full description

Saved in:
Bibliographic Details
Published in:Gastrointestinal endoscopy 2021-02, Vol.93 (2), p.457-466
Main Authors: Roos, Victorine H., Bastiaansen, Barbara A., Kallenberg, Frank G.J., Aelvoet, Arthur S., Bossuyt, Patrick M.M., Fockens, Paul, Dekker, Evelien
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c396t-5e0d42f1804b72b11a25abd3ce67c6557e94f939742e3cda8fd7fb3ffd609f873
cites cdi_FETCH-LOGICAL-c396t-5e0d42f1804b72b11a25abd3ce67c6557e94f939742e3cda8fd7fb3ffd609f873
container_end_page 466
container_issue 2
container_start_page 457
container_title Gastrointestinal endoscopy
container_volume 93
creator Roos, Victorine H.
Bastiaansen, Barbara A.
Kallenberg, Frank G.J.
Aelvoet, Arthur S.
Bossuyt, Patrick M.M.
Fockens, Paul
Dekker, Evelien
description Almost all patients with familial adenomatous polyposis (FAP) develop duodenal adenomas, with a 4% to 18% risk of progression into duodenal cancer. Prophylactic endoscopic resection of duodenal adenomas may prevent cancer and is considered safer than surgical alternatives; however, data are limited. Therefore, the aim of this study was to assess safety and effectiveness of endoscopic duodenal interventions in patients with FAP. We performed a historical cohort study including patients with FAP who underwent an endoscopic duodenal intervention between 2002 and 2018. Safety was defined as adverse event rate per intervention and effectiveness as duodenal surgery–free and duodenal cancer–free survival. Change in Spigelman stage was assessed as a secondary outcome. In 68 endoscopy sessions, 139 duodenal polypectomies were performed in 49 patients (20 men; median age, 43). Twenty-nine patients (14 men; median age, 49) underwent a papillectomy. After polypectomy, 9 (13%) bleedings and 1 (2%) perforation occurred, all managed endoscopically. Six (21%) bleedings (endoscopically managed), 4 (14%) cases of pancreatitis, and 1 (3%) perforation (conservatively treated) occurred after papillectomy. Duodenal surgery–free survival was 74% at 89 months after polypectomy and 71% at 71 months after papillectomy; no duodenal cancers were observed. After a median of 18 months (interquartile range, 10-40; range, 3-121) after polypectomy, Spigelman stages were significantly lower (P < .01). In our FAP patients, prophylactic duodenal polypectomies were relatively safe. Papillectomies showed substantial adverse events, suggesting its benefits and risk should be carefully weighted. Both were effective, however, because surgical interventions were limited and none developed duodenal cancer.
doi_str_mv 10.1016/j.gie.2020.05.065
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2414012616</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0016510720344230</els_id><sourcerecordid>2414012616</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-5e0d42f1804b72b11a25abd3ce67c6557e94f939742e3cda8fd7fb3ffd609f873</originalsourceid><addsrcrecordid>eNp9kMFO3DAQhq2KqmyhD8AF-cgl6diO7Y16QmihlZB6aS9cLMceb71K4jTOgnh7vFoKt57mMN__a-Yj5IJBzYCpr7t6G7HmwKEGWYOSH8iKQasrpXV7QlZQoEoy0Kfkc847AFhzwT6RU8GlkKyFFXnYjD5ll6bo6GBHu8UBx4WmQP0-eRxtT20ZabCZxpFOdolln-lTXP7QYIfYx3dkSftMp9Q_TynHfE4-Bttn_PI6z8jv282vm-_V_c-7HzfX95UTrVoqieAbHtgamk7zjjHLpe28cKi0U1JqbJvQilY3HIXzdh28Dp0IwStow1qLM3J17J3m9HePeTFDzA773o5YDjK8YQ0wrpgqKDuibk45zxjMNMfBzs-GgTkoNTtTlJqDUgPSFKUlc_lav-8G9G-Jfw4L8O0IYHnyMeJssiuSHPo4o1uMT_E_9S8kRohT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2414012616</pqid></control><display><type>article</type><title>Endoscopic management of duodenal adenomas in patients with familial adenomatous polyposis</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>Roos, Victorine H. ; Bastiaansen, Barbara A. ; Kallenberg, Frank G.J. ; Aelvoet, Arthur S. ; Bossuyt, Patrick M.M. ; Fockens, Paul ; Dekker, Evelien</creator><creatorcontrib>Roos, Victorine H. ; Bastiaansen, Barbara A. ; Kallenberg, Frank G.J. ; Aelvoet, Arthur S. ; Bossuyt, Patrick M.M. ; Fockens, Paul ; Dekker, Evelien</creatorcontrib><description>Almost all patients with familial adenomatous polyposis (FAP) develop duodenal adenomas, with a 4% to 18% risk of progression into duodenal cancer. Prophylactic endoscopic resection of duodenal adenomas may prevent cancer and is considered safer than surgical alternatives; however, data are limited. Therefore, the aim of this study was to assess safety and effectiveness of endoscopic duodenal interventions in patients with FAP. We performed a historical cohort study including patients with FAP who underwent an endoscopic duodenal intervention between 2002 and 2018. Safety was defined as adverse event rate per intervention and effectiveness as duodenal surgery–free and duodenal cancer–free survival. Change in Spigelman stage was assessed as a secondary outcome. In 68 endoscopy sessions, 139 duodenal polypectomies were performed in 49 patients (20 men; median age, 43). Twenty-nine patients (14 men; median age, 49) underwent a papillectomy. After polypectomy, 9 (13%) bleedings and 1 (2%) perforation occurred, all managed endoscopically. Six (21%) bleedings (endoscopically managed), 4 (14%) cases of pancreatitis, and 1 (3%) perforation (conservatively treated) occurred after papillectomy. Duodenal surgery–free survival was 74% at 89 months after polypectomy and 71% at 71 months after papillectomy; no duodenal cancers were observed. After a median of 18 months (interquartile range, 10-40; range, 3-121) after polypectomy, Spigelman stages were significantly lower (P &lt; .01). In our FAP patients, prophylactic duodenal polypectomies were relatively safe. Papillectomies showed substantial adverse events, suggesting its benefits and risk should be carefully weighted. Both were effective, however, because surgical interventions were limited and none developed duodenal cancer.</description><identifier>ISSN: 0016-5107</identifier><identifier>EISSN: 1097-6779</identifier><identifier>DOI: 10.1016/j.gie.2020.05.065</identifier><identifier>PMID: 32535190</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><ispartof>Gastrointestinal endoscopy, 2021-02, Vol.93 (2), p.457-466</ispartof><rights>2021 American Society for Gastrointestinal Endoscopy</rights><rights>Copyright © 2021 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-5e0d42f1804b72b11a25abd3ce67c6557e94f939742e3cda8fd7fb3ffd609f873</citedby><cites>FETCH-LOGICAL-c396t-5e0d42f1804b72b11a25abd3ce67c6557e94f939742e3cda8fd7fb3ffd609f873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32535190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roos, Victorine H.</creatorcontrib><creatorcontrib>Bastiaansen, Barbara A.</creatorcontrib><creatorcontrib>Kallenberg, Frank G.J.</creatorcontrib><creatorcontrib>Aelvoet, Arthur S.</creatorcontrib><creatorcontrib>Bossuyt, Patrick M.M.</creatorcontrib><creatorcontrib>Fockens, Paul</creatorcontrib><creatorcontrib>Dekker, Evelien</creatorcontrib><title>Endoscopic management of duodenal adenomas in patients with familial adenomatous polyposis</title><title>Gastrointestinal endoscopy</title><addtitle>Gastrointest Endosc</addtitle><description>Almost all patients with familial adenomatous polyposis (FAP) develop duodenal adenomas, with a 4% to 18% risk of progression into duodenal cancer. Prophylactic endoscopic resection of duodenal adenomas may prevent cancer and is considered safer than surgical alternatives; however, data are limited. Therefore, the aim of this study was to assess safety and effectiveness of endoscopic duodenal interventions in patients with FAP. We performed a historical cohort study including patients with FAP who underwent an endoscopic duodenal intervention between 2002 and 2018. Safety was defined as adverse event rate per intervention and effectiveness as duodenal surgery–free and duodenal cancer–free survival. Change in Spigelman stage was assessed as a secondary outcome. In 68 endoscopy sessions, 139 duodenal polypectomies were performed in 49 patients (20 men; median age, 43). Twenty-nine patients (14 men; median age, 49) underwent a papillectomy. After polypectomy, 9 (13%) bleedings and 1 (2%) perforation occurred, all managed endoscopically. Six (21%) bleedings (endoscopically managed), 4 (14%) cases of pancreatitis, and 1 (3%) perforation (conservatively treated) occurred after papillectomy. Duodenal surgery–free survival was 74% at 89 months after polypectomy and 71% at 71 months after papillectomy; no duodenal cancers were observed. After a median of 18 months (interquartile range, 10-40; range, 3-121) after polypectomy, Spigelman stages were significantly lower (P &lt; .01). In our FAP patients, prophylactic duodenal polypectomies were relatively safe. Papillectomies showed substantial adverse events, suggesting its benefits and risk should be carefully weighted. Both were effective, however, because surgical interventions were limited and none developed duodenal cancer.</description><issn>0016-5107</issn><issn>1097-6779</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kMFO3DAQhq2KqmyhD8AF-cgl6diO7Y16QmihlZB6aS9cLMceb71K4jTOgnh7vFoKt57mMN__a-Yj5IJBzYCpr7t6G7HmwKEGWYOSH8iKQasrpXV7QlZQoEoy0Kfkc847AFhzwT6RU8GlkKyFFXnYjD5ll6bo6GBHu8UBx4WmQP0-eRxtT20ZabCZxpFOdolln-lTXP7QYIfYx3dkSftMp9Q_TynHfE4-Bttn_PI6z8jv282vm-_V_c-7HzfX95UTrVoqieAbHtgamk7zjjHLpe28cKi0U1JqbJvQilY3HIXzdh28Dp0IwStow1qLM3J17J3m9HePeTFDzA773o5YDjK8YQ0wrpgqKDuibk45zxjMNMfBzs-GgTkoNTtTlJqDUgPSFKUlc_lav-8G9G-Jfw4L8O0IYHnyMeJssiuSHPo4o1uMT_E_9S8kRohT</recordid><startdate>202102</startdate><enddate>202102</enddate><creator>Roos, Victorine H.</creator><creator>Bastiaansen, Barbara A.</creator><creator>Kallenberg, Frank G.J.</creator><creator>Aelvoet, Arthur S.</creator><creator>Bossuyt, Patrick M.M.</creator><creator>Fockens, Paul</creator><creator>Dekker, Evelien</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202102</creationdate><title>Endoscopic management of duodenal adenomas in patients with familial adenomatous polyposis</title><author>Roos, Victorine H. ; Bastiaansen, Barbara A. ; Kallenberg, Frank G.J. ; Aelvoet, Arthur S. ; Bossuyt, Patrick M.M. ; Fockens, Paul ; Dekker, Evelien</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-5e0d42f1804b72b11a25abd3ce67c6557e94f939742e3cda8fd7fb3ffd609f873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roos, Victorine H.</creatorcontrib><creatorcontrib>Bastiaansen, Barbara A.</creatorcontrib><creatorcontrib>Kallenberg, Frank G.J.</creatorcontrib><creatorcontrib>Aelvoet, Arthur S.</creatorcontrib><creatorcontrib>Bossuyt, Patrick M.M.</creatorcontrib><creatorcontrib>Fockens, Paul</creatorcontrib><creatorcontrib>Dekker, Evelien</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gastrointestinal endoscopy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roos, Victorine H.</au><au>Bastiaansen, Barbara A.</au><au>Kallenberg, Frank G.J.</au><au>Aelvoet, Arthur S.</au><au>Bossuyt, Patrick M.M.</au><au>Fockens, Paul</au><au>Dekker, Evelien</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Endoscopic management of duodenal adenomas in patients with familial adenomatous polyposis</atitle><jtitle>Gastrointestinal endoscopy</jtitle><addtitle>Gastrointest Endosc</addtitle><date>2021-02</date><risdate>2021</risdate><volume>93</volume><issue>2</issue><spage>457</spage><epage>466</epage><pages>457-466</pages><issn>0016-5107</issn><eissn>1097-6779</eissn><abstract>Almost all patients with familial adenomatous polyposis (FAP) develop duodenal adenomas, with a 4% to 18% risk of progression into duodenal cancer. Prophylactic endoscopic resection of duodenal adenomas may prevent cancer and is considered safer than surgical alternatives; however, data are limited. Therefore, the aim of this study was to assess safety and effectiveness of endoscopic duodenal interventions in patients with FAP. We performed a historical cohort study including patients with FAP who underwent an endoscopic duodenal intervention between 2002 and 2018. Safety was defined as adverse event rate per intervention and effectiveness as duodenal surgery–free and duodenal cancer–free survival. Change in Spigelman stage was assessed as a secondary outcome. In 68 endoscopy sessions, 139 duodenal polypectomies were performed in 49 patients (20 men; median age, 43). Twenty-nine patients (14 men; median age, 49) underwent a papillectomy. After polypectomy, 9 (13%) bleedings and 1 (2%) perforation occurred, all managed endoscopically. Six (21%) bleedings (endoscopically managed), 4 (14%) cases of pancreatitis, and 1 (3%) perforation (conservatively treated) occurred after papillectomy. Duodenal surgery–free survival was 74% at 89 months after polypectomy and 71% at 71 months after papillectomy; no duodenal cancers were observed. After a median of 18 months (interquartile range, 10-40; range, 3-121) after polypectomy, Spigelman stages were significantly lower (P &lt; .01). In our FAP patients, prophylactic duodenal polypectomies were relatively safe. Papillectomies showed substantial adverse events, suggesting its benefits and risk should be carefully weighted. Both were effective, however, because surgical interventions were limited and none developed duodenal cancer.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32535190</pmid><doi>10.1016/j.gie.2020.05.065</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0016-5107
ispartof Gastrointestinal endoscopy, 2021-02, Vol.93 (2), p.457-466
issn 0016-5107
1097-6779
language eng
recordid cdi_proquest_miscellaneous_2414012616
source Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)
title Endoscopic management of duodenal adenomas in patients with familial adenomatous polyposis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T07%3A05%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Endoscopic%20management%20of%20duodenal%20adenomas%20in%20patients%20with%20familial%20adenomatous%20polyposis&rft.jtitle=Gastrointestinal%20endoscopy&rft.au=Roos,%20Victorine%20H.&rft.date=2021-02&rft.volume=93&rft.issue=2&rft.spage=457&rft.epage=466&rft.pages=457-466&rft.issn=0016-5107&rft.eissn=1097-6779&rft_id=info:doi/10.1016/j.gie.2020.05.065&rft_dat=%3Cproquest_cross%3E2414012616%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c396t-5e0d42f1804b72b11a25abd3ce67c6557e94f939742e3cda8fd7fb3ffd609f873%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2414012616&rft_id=info:pmid/32535190&rfr_iscdi=true